Merrem I.V. Shortage May Continue Into 2006
This article was originally published in The Pink Sheet Daily
Executive Summary
Short supply of AstraZeneca's antibiotic is attributed to manufacturing delays and increased demand.
You may also be interested in...
Merrem I.V. Shortage Due To Increased Regional Demand, AstraZeneca Says
FDA’s website states the antibiotic shortage stems from “manufacturing delays due to bulk drug supply shortages.” The company does not plan to ration shipments to U.S. regions that are not experiencing increased demand.
Lipitor Pricing Offsets Loss In Prescription Volume, Pfizer Says
Declines in Lipitor's prescription volume due to the presence of generic simvastatin are being offset by price increases, Pfizer says
Mail-Order Pharmacy Not Necessarily Cheaper To Health Plans, Ohio Finds
Health plans should account for the rise in utilization that occurs with use of mail-order pharmacy when deciding if mail order saves money, Ohio Public Employees Retirement System Director of Healthcare Scott Streator said at the recent Academy of Managed Care Pharmacy Educational Conference in Chicago